Monday, September 7, 2026
60 articles analyzed
Updated Sep 7, 9:14 PM · 60 sources analyzed
Key Takeaways
Novo Nordisk killed both HERMES and ATHENA ziltivekimab trials, dealing a serious blow to anti-inflammatory cardiovascular drug development broadly.
GSK paid $110M for a Phase 1-ready bispecific ATTC from Hutchmed, signaling continued appetite for novel oncology modalities before clinical proof-of-concept.
Eli Lilly terminated its LY3549492 Phase 2 obesity program, underscoring the rising internal bar for next-generation weight loss assets beyond orforglipron.
🏆 Winner
GSK — secured a first-mover position in a novel bispecific antibody-targeted therapy conjugate modality for $110M before any competing clinical data exist.
📉 Loser
Novo Nordisk — simultaneous termination of two Phase 3 cardiovascular inflammation trials eliminates a key pipeline diversification opportunity outside GLP-1.
🔭 Watch Next
Full efficacy data from Takeda's completed Phase 3 HERMES study of oveporexton in Narcolepsy Type 1 are the most consequential pending readout visible in today's sources, expected at a sleep medicine conference in the next one to two quarters.
Novo Nordisk halts two ziltivekimab cardiovascular trials
Novo Nordisk has stopped the HERMES and ATHENA trials of ziltivekimab, its anti-inflammation cardiovascular drug, following a data monitoring committee review. The terminations are a significant blow to the hypothesis that targeting IL-6 ligand-driven inflammation can reduce cardiovascular events, a concept that has already suffered setbacks across the industry. For Novo Nordisk, whose growth story is anchored in GLP-1 obesity drugs, this eliminates a potential cardiovascular franchise diversification play and reinforces how difficult it has been to replicate the Canakinumab Anti-inflammatory Thrombosis Outcome Study (CANTOS) success in broader cardiovascular populations.
STAT News ↗Novo Nordisk
Ziltivekimab in Cardiovascular disease / inflammation
The HERMES and ATHENA trials were stopped following a data monitoring committee review. The company disclosed the trial halts without providing full numerical efficacy or safety data; detailed results have not yet been released.
Why it matters
This is a costly strategic setback: ziltivekimab was Novo Nordisk's most advanced bet on cardiovascular inflammation outside its GLP-1 franchise, and losing both HERMES and ATHENA in one move removes a meaningful pipeline diversification option. The company will need to explain whether the failure was drug-specific or hypothesis-specific — the answer has implications for the entire anti-inflammatory cardiovascular space.
What to watch
Watch for Novo Nordisk's investor call or publication of the underlying DMC data, expected in coming months, which will clarify whether the failure reflects efficacy shortfalls, safety signals, or both — and whether the anti-IL-6 CV hypothesis survives for competitors.
GSK / Hutchmed
GSK paid $110M upfront to license a Phase 1-ready antibody-targeted therapy conjugate (ATTC) from Hutchmed for lung, colorectal, and pancreatic cancer development.
This deal gives GSK a first-mover position in a novel bispecific-plus-payload modality before any clinical efficacy data exist, betting that early entry in a new drug class creates durable competitive advantage in hard-to-treat solid tumors.
Why it matters
GSK's willingness to pay $110M for a preclinical-to-Phase-1-ready asset underscores how much the oncology BD market has shifted toward acquiring modality novelty rather than waiting for Phase 2 proof of concept — a dynamic that rewards biotech platforms with differentiated biology early. For Hutchmed, this is a meaningful validation event for a company that has historically been stronger in Asia than in Western partnership circles.
What to watch
Watch for GSK's oncology pipeline update at its next investor event, where the ATTC asset's development plan and lead indication prioritization should be clarified, and for any milestone payments tied to Phase 1 initiation.
GSK acquires Phase 1-ready bispecific antibody-drug conjugate from Hutchmed for $110M
GSK licensed a first-in-class antibody-targeted therapy conjugate (ATTC) from Hutchmed — a dual-blocking agent that simultaneously inhibits two cancer-driving proteins — for $110 million, with initial development targeted at lung, colorectal, and pancreatic cancers.
Why it matters
At $110M for a Phase 1-ready asset in three high-volume solid tumor indications, GSK is making a credible early bet on a novel modality before clinical proof-of-concept is established — consistent with its stated strategy of building in oncology through external innovation. Hutchmed gains non-dilutive capital and validation for a platform that has struggled for broader partnering attention.
What to watch
Watch for IND activation and Phase 1 dosing initiation, expected within the next 12 months, and for GSK to disclose which of the three tumor types will serve as the lead indication in first-in-human studies.
Allosteric pathways control which G protein a GPCR activates
A bioRxiv preprint identifies structural allosteric pathways (internal communication routes within a receptor protein) that determine which G protein a promiscuous GPCR (a receptor that can engage multiple signaling partners) selects, providing a mechanistic explanation for coupling selectivity.
Why it matters
GPCRs represent the target class for roughly one-third of approved drugs, but biased agonism has remained difficult to engineer rationally. If these allosteric pathway maps hold up in peer review and broader receptor families, they could meaningfully accelerate structure-guided drug design programs at companies with GPCR-heavy pipelines.
What to watch
Watch for peer-reviewed publication of this preprint and whether any major GPCR-focused drug discovery companies — including those with biased agonist programs in GLP-1R, opioid, or beta-arrestin biology — cite or build on this structural framework in their platform updates.
The HERMES and ATHENA trials were stopped following a data monitoring committee review. The company disclosed the trial halts without providing full numerical efficacy or safety data; detailed results have not yet been released.
Why it matters
Killing two late-stage cardiovascular inflammation trials simultaneously signals the anti-IL-6 cardiovascular hypothesis may not deliver the broad benefit investors and the field had hoped for, narrowing the competitive field and raising questions about other inflammation-targeting CV programs.
Analysis
This is a costly strategic setback: ziltivekimab was Novo Nordisk's most advanced bet on cardiovascular inflammation outside its GLP-1 franchise, and losing both HERMES and ATHENA in one move removes a meaningful pipeline diversification option. The company will need to explain whether the failure was drug-specific or hypothesis-specific — the answer has implications for the entire anti-inflammatory cardiovascular space.
What to watch
Watch for Novo Nordisk's investor call or publication of the underlying DMC data, expected in coming months, which will clarify whether the failure reflects efficacy shortfalls, safety signals, or both — and whether the anti-IL-6 CV hypothesis survives for competitors.
The Phase 3 study of TAK-861 (oveporexton) in Narcolepsy Type 1 has been marked as completed on ClinicalTrials.gov. The primary endpoint was improvement in excessive daytime sleepiness after 3 months of treatment. Full efficacy and safety data have not been released in the available sources.
Why it matters
Narcolepsy Type 1 is a high-unmet-need orphan indication with limited approved options; a completed Phase 3 for an orexin receptor agonist could set up a near-term NDA filing if data support efficacy.
Analysis
Completion of this registrational study moves oveporexton to the data readout stage, which will determine whether Takeda can challenge Jazz Pharmaceuticals' dominance in narcolepsy with a mechanistically differentiated orexin-targeted agent. The investment thesis hinges entirely on what the efficacy numbers show when disclosed.
What to watch
Watch for full Phase 3 data disclosure at a sleep medicine conference or in a peer-reviewed publication in the next one to two quarters, and any subsequent NDA filing announcement.
The Phase 3 STRIDES study — a multicenter, randomized, double-blind, placebo-controlled trial of intra-articular lorecivivint in moderately to severely symptomatic knee osteoarthritis — has been marked as completed on ClinicalTrials.gov. Full efficacy and safety data have not yet been released.
Why it matters
Knee osteoarthritis has no approved disease-modifying therapy; a Phase 3 completion for a Wnt pathway-targeting small molecule is a meaningful registry event in a field starved for structural options.
Analysis
Lorecivivint has had a mixed clinical history with earlier Phase 2b results showing subgroup-dependent efficacy, so the STRIDES Phase 3 data — when released — will be the definitive test of whether the Wnt pathway modulation approach works broadly or only in select patients. Investors and potential acquirers will scrutinize whether this was a clean win or another nuanced read.
What to watch
Watch for public release of STRIDES efficacy data, likely at an orthopedic or rheumatology congress in late 2026 or early 2027, which will determine the regulatory filing path.
The Phase 2 RewinD-LB study evaluating neflamapimod — a p38 MAPK inhibitor (an enzyme involved in neuroinflammation) — for cognitive outcomes in Dementia with Lewy Bodies has been marked as completed on ClinicalTrials.gov. Detailed efficacy data have not yet been released.
Why it matters
Dementia with Lewy Bodies has no approved cognitive therapies; any signal from a kinase-targeting approach in this indication could draw partnership interest from larger neuroscience players.
Analysis
EIP Pharma has positioned neflamapimod as a synaptic rescue agent in neurodegenerative diseases; results from RewinD-LB will test whether the cognitive benefits seen in earlier Alzheimer's Disease work translate to DLB, a notoriously difficult-to-treat population. The outcome will shape whether the p38 MAPK pathway remains viable in neurodegeneration.
What to watch
Watch for RewinD-LB data presentation at a neurology or dementia-focused conference in Q4 2026, which will determine whether EIP Pharma pursues a Phase 3 or seeks a partnership ahead of further investment.
The Phase 2 study of LY3549492 in adults with obesity or overweight and Type 2 diabetes has been marked as terminated on ClinicalTrials.gov. No efficacy or safety data have been released to explain the termination.
Why it matters
Lilly is aggressively pruning its obesity pipeline, and a terminated asset in this crowded space is a signal that even the best-resourced sponsor will cut programs that do not differentiate — the bar for next-generation obesity drugs continues to rise.
Analysis
The termination of LY3549492 is unlikely to move Lilly's investment thesis given the depth of its tirzepatide and orforglipron programs, but it does underscore that the company is actively rationalizing its obesity portfolio and not advancing every mechanism that enters the clinic. Investors should watch whether Lilly replaces this with a differentiated mechanism or doubles down on oral GLP-1.
What to watch
Watch for Lilly's next pipeline update — likely at an investor event in late 2026 — which should clarify how LY3549492 termination affects its broader obesity asset prioritization beyond orforglipron.
GSK / Hutchmed
GSK paid $110M upfront to license a Phase 1-ready antibody-targeted therapy conjugate (ATTC) from Hutchmed for lung, colorectal, and pancreatic cancer development.
Why it matters
This deal gives GSK a first-mover position in a novel bispecific-plus-payload modality before any clinical efficacy data exist, betting that early entry in a new drug class creates durable competitive advantage in hard-to-treat solid tumors.
Analysis
GSK's willingness to pay $110M for a preclinical-to-Phase-1-ready asset underscores how much the oncology BD market has shifted toward acquiring modality novelty rather than waiting for Phase 2 proof of concept — a dynamic that rewards biotech platforms with differentiated biology early. For Hutchmed, this is a meaningful validation event for a company that has historically been stronger in Asia than in Western partnership circles.
What to watch
Watch for GSK's oncology pipeline update at its next investor event, where the ATTC asset's development plan and lead indication prioritization should be clarified, and for any milestone payments tied to Phase 1 initiation.
Allosteric pathways control which G protein a GPCR activates
A bioRxiv preprint identifies structural allosteric pathways (internal communication routes within a receptor protein) that determine which G protein a promiscuous GPCR (a receptor that can engage multiple signaling partners) selects, providing a mechanistic explanation for coupling selectivity.
Why it matters
Understanding these allosteric routes could enable design of biased agonists (drugs that selectively activate only the therapeutically useful signaling arm of a receptor) with higher precision, reducing off-target side effects for GPCR-targeted drugs across cardiovascular, CNS, and metabolic indications.
Analysis
GPCRs represent the target class for roughly one-third of approved drugs, but biased agonism has remained difficult to engineer rationally. If these allosteric pathway maps hold up in peer review and broader receptor families, they could meaningfully accelerate structure-guided drug design programs at companies with GPCR-heavy pipelines.
What to watch
Watch for peer-reviewed publication of this preprint and whether any major GPCR-focused drug discovery companies — including those with biased agonist programs in GLP-1R, opioid, or beta-arrestin biology — cite or build on this structural framework in their platform updates.
Small molecule blocks CD28 costimulation without disrupting CTLA-4 in IBD models
A bioRxiv preprint describes a small molecule inhibitor of CD28 costimulation (the signal that activates inflammatory T cells) identified via NanoBiT split-luciferase screening, which selectively restrains pathogenic T-cell responses in inflammatory bowel disease models without also blocking CTLA-4 — a limitation of existing biologics like abatacept.
Why it matters
Selective CD28 blockade could offer a safer and orally deliverable alternative to current B7-directed biologics for IBD, potentially expanding the addressable patient population and reducing the immunosuppression burden associated with full costimulation blockade.
Analysis
This is early-stage work, but the selectivity profile matters: the field has long wanted a way to dampen pathogenic T cells in autoimmune conditions without disabling the CTLA-4 brake that protects against runaway immunosuppression. If the specificity holds in vivo, this could attract interest from companies with IBD pipelines looking for a next-generation oral mechanism.
What to watch
Watch for peer-reviewed publication and any follow-on in vivo efficacy studies in IBD models, which will determine whether the selectivity advantage translates out of cell-based systems and justifies IND-enabling work.
GSK acquires Phase 1-ready bispecific antibody-drug conjugate from Hutchmed for $110M
GSK licensed a first-in-class antibody-targeted therapy conjugate (ATTC) from Hutchmed — a dual-blocking agent that simultaneously inhibits two cancer-driving proteins — for $110 million, with initial development targeted at lung, colorectal, and pancreatic cancers.
Why it matters
The ATTC format represents a potential advance over standard ADCs (antibody-drug conjugates, which typically deliver a cytotoxic payload to cancer cells) by combining dual-target blockade with targeted delivery, which could improve efficacy in tumors that co-express multiple oncogenic drivers.
Analysis
At $110M for a Phase 1-ready asset in three high-volume solid tumor indications, GSK is making a credible early bet on a novel modality before clinical proof-of-concept is established — consistent with its stated strategy of building in oncology through external innovation. Hutchmed gains non-dilutive capital and validation for a platform that has struggled for broader partnering attention.
What to watch
Watch for IND activation and Phase 1 dosing initiation, expected within the next 12 months, and for GSK to disclose which of the three tumor types will serve as the lead indication in first-in-human studies.
Oral GLP-1 competing directly with Lilly and Novo. Best-in-class efficacy in Phase 2 at ~15% weight loss. Phase 3 success could make Viking an M&A target.
No coverage today
None of your tracked companies appeared in today's sources.
Every weekday morning
Start your morning with the stories moving biotech.
Clinical readouts · FDA watch · Deal flow · Pipeline pulse